RxDoctor Payments Data

Thomas Smith

Critical Care Medicine · Albany, NYNPI 1134115306

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,148 of the $3,290 with a category attached, or 65.3%. AstraZeneca accounts for 79.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $2,527 and has fallen 99.3% since, to $17 in 2025.

$3,290in general payments, 2019–2025

Across 19 payments — averaging $173.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$488
  • Chiesi USA, Inc.$138
  • Pfizer$33
  • Sanofi Pasteur Inc.$17
$533,314in research payments, 2019–2025

Across 18 payments — averaging $29,629 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$533K
  • Vivus LLC$324

What the payments were for

  • Consulting fees$2,14865%
  • Food & beverage$1,12834%
  • Education$140%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca6$2,614
GSK6$488
Chiesi USA, Inc.4$138
Pfizer2$33
Sanofi Pasteur Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,290 in reported general payments places this provider in the 85th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York →

Other critical care medicine in Albany

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →